Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Gross Margin (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Gross Margin for 3 consecutive years, with 86.72% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin fell 42.0% to 86.72% in Q4 2025 year-over-year; TTM through Dec 2025 was 87.09%, a 152.0% increase, with the full-year FY2025 number at 87.09%, up 152.0% from a year prior.
  • Gross Margin was 86.72% for Q4 2025 at Phathom Pharmaceuticals, down from 87.5% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 87.5% in Q3 2025 to a low of 75.51% in Q4 2023.
  • A 3-year average of 83.95% and a median of 86.72% in 2025 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: skyrocketed 1163bps in 2024, then crashed -42bps in 2025.
  • Phathom Pharmaceuticals' Gross Margin stood at 75.51% in 2023, then grew by 15bps to 87.14% in 2024, then fell by 0bps to 86.72% in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Gross Margin are 86.72% (Q4 2025), 87.5% (Q3 2025), and 87.25% (Q2 2025).